NGNE Projected Dividend Yield
Neurogene Inc ( NASDAQ : NGNE )Neurogene Inc. is a clinical-stage biotechnology company. Co., through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. 20 YEAR PERFORMANCE RESULTS |
NGNE Dividend History Detail NGNE Dividend News NGNE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |